ZFIN ID: ZDB-FIG-170227-15
De Angelis et al., 2017 - Tmem2 Regulates Embryonic Vegf Signaling by Controlling Hyaluronic Acid Turnover. Developmental Cell   40:123-136 Full text @ Dev. Cell
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Gene:
Antibody:
Fish:
Anatomical Term:
Stage: 26+ somites
PHENOTYPE:
Fish:
Condition:
Knockdown Reagents:
Observed In:
Stage Range: 26+ somites to Prim-25

Fig. 5

Rescue of the tmem2hu5935 Mutant Phenotype by Degrading HA Requires the Vegf Pathway

(A) Whole-mount pErk immunofluorescence staining (white) in sibling and tmem2hu5935 mutants on the Tg(kdrl:EGFP) background (green) at 22 hpf, injected just 3 hr prior with dextran. Scale bar, 10 μm.

(B) Graph depicting the significant reduction in fluorescence intensity of pErk-positive endothelial cells in mutants (n = 43) versus sibling embryos (n = 56) following dextran injection.

(C) Whole-mount pErk immunofluorescence staining in sibling and mutant embryos 3 hr after HA'se injection. Scale bar, 10 μm.

(D) Scatterplots showing no significant difference in fluorescence intensity of pErk-positive endothelial cells in mutants (n = 90) versus sibling embryos following HA'se injection (n = 89).

(E) Untreated vegfaa morphants (n = 8) had fewer ISVs compared with uninjected controls (n = 10) and this reduction in sprouting was not significantly different following HA'se (n = 8), o-HA (n = 11) or HA'se inact treatment (n = 9).

(F) Likewise, untreated kdr/kdrl double morphants (n = 25) had no detectable ISVs compared with normal uninjected controls (n = 11), and this loss of sprouting was not significantly different following HA'se (n = 17), o-HA (n = 20) or HA'se inact treatment (n = 20).

(G) Design of rescue experiments for low and high dose SU5416 treatments shown in (H) and (I).

(H) Scatterplot for DMSO-treated embryos injected with HA'se (n = 27), o-HA (n = 29), or HA'se inact (n = 23) showing no difference from uninjected (n = 8) embryos. Low-dose (0.8 μM) SU5416 mildly but significantly impaired ISV sprouting in uninjected embryos (n = 21). SU5416-treated embryos injected with HA'se (n = 40) or HA'se inact (n = 46) were not significantly different from uninjected but o-HA injected embryos (n = 53) were significantly rescued (p < 0.0001).

(I) At a higher dose (1 μM SU5416), DMSO treatment again had no effect on embryos not injected (n = 8), injected with HA'se (n = 12), o-HA (n = 16), or HA'se inact (n = 11). At the higher dose, all treatments (uninjected [n = 13], HA'se [n = 12], o-HA [n = 18] and HA'se inact [n = 11]) were significantly different from DMSO with no rescue in any of these conditions observed. For all scatterplots uninjected (white circles), HA'se injected (yellow squares), o-HA injected (gray triangles), HA'se inact (red diamonds). ∗∗p < 0.01, ∗∗∗∗p < 0.0001. Error bars represent ±SD.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
EGFP cemip2hu5935/hu5935; s843Tg standard conditions 26+ somites dorsal aorta endothelial cell IHC
s843Tg standard conditions 26+ somites dorsal aorta endothelial cell IHC
Antibody Labeling Details
Antibody Assay Fish Conditions Stage Anatomy
Ab9-mapk IHC cemip2hu5935/hu5935; s843Tg standard conditions 26+ somites dorsal aorta endothelial cell
IHC s843Tg standard conditions 26+ somites dorsal aorta endothelial cell
Phenotype Details
Fish Conditions Stage Phenotype
WT chemical treatment by environment: semaxanib Prim-25 intersegmental vessel decreased amount, abnormal
WT + MO1-kdr + MO4-kdrl standard conditions Prim-25 intersegmental vessel decreased amount, abnormal
WT + MO2-vegfaa standard conditions Prim-25 intersegmental vessel decreased amount, abnormal
s843Tg standard conditions 26+ somites dorsal aorta endothelial cell ab9-mapk labeling decreased amount, abnormal
26+ somites dorsal aorta endothelial cell ab9-mapk labeling decreased distribution, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Developmental Cell for permission to reproduce figures from this article. Please note that this material may be protected by copyright.

Reprinted from Developmental Cell, 40, De Angelis, J.E., Lagendijk, A.K., Chen, H., Tromp, A., Bower, N.I., Tunny, K.A., Brooks, A.J., Bakkers, J., Francois, M., Yap, A.S., Simons, C., Wicking, C., Hogan, B.M., Smith, K.A., Tmem2 Regulates Embryonic Vegf Signaling by Controlling Hyaluronic Acid Turnover, 123-136, Copyright (2017) with permission from Elsevier. Full text @ Dev. Cell